An interventional study of Standard colonoscopy and Colonoscopy CADe in Colonoscopy, Colorectal Neoplasms and Intestinal Polyps, sponsored by University Hospital, Bordeaux. Recruiting at 15 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 581 studies in Colorectal Neoplasms with a site in France — 110 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.
Among the 581 studies in Colorectal Neoplasms with a site in France, this one is the 78th largest by planned enrollment of the 463 interventional ones that give a count, is one of 19 that started in 2026, is one of 116 with no phase, reaches primary completion later than 162 of the 164 other live ones, and was the 568th registered.
6,544 studies on the registry are indexed under Colorectal Neoplasms; 1,666 are open to participants now.
Browse Colorectal Neoplasms studies →110 of the 581 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Antoine Lacassagne · Sites in France
Ages 18–75
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
EMD Serono Research & Development Institute, Inc. · Sites in France, United States, Argentina and 16 more countries
Ages 18+
University Hospital, Caen · Sites in France
Ages 50–75
Federation Francophone de Cancerologie Digestive · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,184 Colorectal Neoplasms studies recruiting now, 767 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 124 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
581 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 116 · Phase 2 206 · Phase 3 97 · Phase 4 6
First in 1993; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 592 is above the median of 76 across 4,801 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 152 across the 463 interventional studies, 278 across the 102 observational. Of the 356 that completed or were terminated, 105 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
223 of 581 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 5 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Colorectal Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07520578Phase 3University Hospital, CaenEFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO) | 2027-03-24 |
| NCT07361575Clinique Paris-BercyStudy Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG). | 2026-11-15 |
| NCT07116668SafeHeal IncSafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
Add all 38 to your calendar (.ics) → With an account.
Among the 581 studies in Colorectal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The occurrence of interval cancers after colonoscopy raises the possibility of missed lesions. High- performance computer aided diagnosis (CAD) systems have been specially designed for the detection of colorectal lesions (CAD for detection is named CADe). The use of CADe improves adenoma detection in screening colonoscopy. The potential of CADe system in reducing the rate of progression to advanced polyps or interval cancer between two colonoscopies remains still uncertain.
Patients will be enrolled after a pre-colonoscopy consultation and risk-assessment for colorectal cancer. The screening colonoscopy will be performed by an investigator. Patients will be randomized in the endoscopy room after confirmed cecal intubation and quality of bowel preparation. Randomization into two groups: standard colonoscopy vs. colonoscopy with CADe (CAD EYE or GENIUS) (1:1). A follow-up consultation will be scheduled one-month postcolonoscopy for delivery of histological results and then at 3 years in order to organize the next colonoscopy. As part of the study, a new control colonoscopy will be scheduled for patients with high risk of CRC at 3 years. The 3-year control colonoscopy will be performed with the CAD system for all patients. The colonoscopy will be performed by another investigator who does not know the results nor the type of the first colonoscopy (evaluator blinded). In the low-risk group, we will collect follow-up data as part of routine care, including the results of colonoscopies performed outside of the protocol
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be enrolled after a pre-colonoscopy consultation and risk-assessment for colorectal cancer. The screening colonoscopy will be performed by an investigator. Patients will be randomized in the endoscopy room after confirmed cecal intubation and quality of bowel preparation. Patient has standard colonoscopy
Procedure: Standard colonoscopy
Patients will be enrolled after a pre-colonoscopy consultation and risk-assessment for colorectal cancer. The screening colonoscopy will be performed by an investigator. Patients will be randomized in the endoscopy room after confirmed cecal intubation and quality of bowel preparation. Patient has colonoscopy with CADe (CAD EYE or GENIUS)
Procedure: Colonoscopy CADe
Colonoscopy standard (without CADe)
colonoscopy with CADe
Advanced adenoma
The proportion of patients presenting at least one advanced adenoma detected after a 3-year follow-up period. An advanced adenoma is defined as an adenoma or sessile serrate adenoma (SSL) larger than 1cm (size confirmed by the CAD system and/or size estimation by snare), and/or with high-grade dysplasia or neoplasia (confirmed by histological analysis).
Time frame: 36 months
Number of adenoma
Average number of adenoma or SSL (confirmed by histological analysis) detected in each patient during screening colonoscopy after a 3-year follow-up period
Time frame: 36 months
Estimation of the sensitivity of CADx
Estimated sensitivity of CADx (CAD for characterization is named CADx) for the diagnosis and evaluation of colonic polyp's malignancy, with histologic analysis in each center as a reference diagnosis.
Time frame: Day0, 36 months
Estimation of the specificity of CADx
Estimated specificity of CADx (CAD for characterization is named CADx) for the diagnosis and evaluation of colonic polyp's malignancy, with histologic analysis in each center as a reference diagnosis.
Time frame: DAY 0, 36 months
Cost of CADe and classical colonoscopy
The cost of CADe and classical colonoscopy will be estimated using a bottom-up micro costing approach
Time frame: Day 0, 36 months
Started Mar 2026 (actual). Primary completion is estimated for Mar 2031, 60 months after the start.
Of 899 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 60 months is above that.
Counting every sponsor, half of 956 studies reached it within 32 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →